Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike

Memory B cell reserves can generate protective antibodies against repeated SARS-CoV-2 infections, but with an unknown reach from original infection to antigenically drifted variants. We charted memory B cell receptor-encoded monoclonal antibodies (mAbs) from 19 COVID-19 convalescent subjects against SARS-CoV-2 spike (S) and found 7 major mAb competition groups against epitopes recurrently targeted across individuals. Inclusion of published and newly determined structures of mAb-S complexes identified corresponding epitopic regions. Group assignment correlated with cross-CoV-reactivity breadth, neutralization potency, and convergent antibody signatures. mAbs that competed for binding the original S isolate bound differentially to S variants, suggesting the protective importance of otherwise-redundant recognition. The results furnish a global atlas of the S-specific memory B cell repertoire and illustrate properties conferring robustness against emerging SARS-CoV-2 variants.

[1]  D. Neuberg,et al.  Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike , 2021, Cell.

[2]  D. Stuart,et al.  The antigenic anatomy of SARS-CoV-2 receptor binding domain , 2021, Cell.

[3]  A. Iafrate,et al.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[4]  M. Malim,et al.  Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike , 2021, bioRxiv.

[5]  A. Sigal,et al.  Sixteen novel lineages of SARS-CoV-2 in South Africa , 2021, Nature Medicine.

[6]  D. Ho,et al.  Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, Research square.

[7]  Vineet D. Menachery,et al.  Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera , 2021, bioRxiv.

[8]  D. Ho,et al.  Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, bioRxiv.

[9]  M. Nussenzweig,et al.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, bioRxiv.

[10]  P. Dormitzer,et al.  Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.

[11]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[12]  D. Stuart,et al.  ­­­The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain , 2020, SSRN Electronic Journal.

[13]  M. Nussenzweig,et al.  Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo , 2020, The Journal of experimental medicine.

[14]  W. P. Duprex,et al.  Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape , 2020, bioRxiv.

[15]  M. Nussenzweig,et al.  SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.

[16]  I. Wilson,et al.  Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies , 2020, Biochemical and Biophysical Research Communications.

[17]  G. Atwal,et al.  REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, Science.

[18]  D. Burton,et al.  Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection , 2020, bioRxiv.

[19]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[20]  Steven H Kleinstein,et al.  Human germinal centres engage memory and naïve B cells after influenza vaccination , 2020, Nature.

[21]  D. Burton,et al.  Structural basis of a shared antibody response to SARS-CoV-2 , 2020, Science.

[22]  Howard Y. Chang,et al.  Human B cell clonal expansion and convergent antibody responses to SARS CoV-2 , 2020, bioRxiv.

[23]  Qiang Zhou,et al.  A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.

[24]  J. Sodroski,et al.  Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike , 2020, bioRxiv.

[25]  J. Dye,et al.  Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.

[26]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[27]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[28]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[29]  W. Xu,et al.  The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin , 2020, Signal Transduction and Targeted Therapy.

[30]  L. Gieselmann,et al.  Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.

[31]  D. Lauffenburger,et al.  Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production , 2020, Cell.

[32]  L. Stamatatos,et al.  Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.

[33]  Ilya J. Finkelstein,et al.  Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.

[34]  M. Nussenzweig,et al.  Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.

[35]  Marc C. Johnson,et al.  Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein , 2020, Journal of Virology.

[36]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[37]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[38]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[39]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[40]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[41]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[42]  S. Pierce,et al.  B cell memory: building two walls of protection against pathogens , 2019, Nature Reviews Immunology.

[43]  I. Wilson,et al.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. , 2019, Current opinion in virology.

[44]  Spyros Darmanis,et al.  High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes , 2018, Science.

[45]  D. Burton,et al.  Commonality despite exceptional diversity in the baseline human antibody repertoire , 2018, Nature.

[46]  C. Rice,et al.  A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. , 2018, Cell reports.

[47]  Thorsten Wagner,et al.  SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM , 2019, Communications Biology.

[48]  C. Rice,et al.  Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico , 2017, Cell.

[49]  D. Agard,et al.  MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy , 2017, Nature Methods.

[50]  N. Grigorieff,et al.  CTFFIND4: Fast and accurate defocus estimation from electron micrographs , 2015, bioRxiv.

[51]  T. Kepler,et al.  Viral Receptor-Binding Site Antibodies with Diverse Germline Origins , 2015, Cell.

[52]  Sjors H.W. Scheres,et al.  RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.

[53]  J. Yewdell,et al.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of Experimental Medicine.

[54]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[55]  David N Mastronarde,et al.  Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.

[56]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[57]  D. Calado,et al.  Germinal Centers , 2017, Methods in Molecular Biology.

[58]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.